✦ LIBER ✦

Results from AMBER, a randomized phase 2 study of bevacizumab and bortezomib versus bortezomib in relapsed or refractory multiple myeloma

✍ Scribed by Darrell White; Adetola Kassim; Birbal Bhaskar; Jing Yi; Karen Wamstad; Virginia E. Paton

Book ID: 112067286
Publisher: John Wiley and Sons
Year: 2012
Tongue: English
Weight: 910 KB
Volume: 119
Category: Article
ISSN: 0008-543X
DOI: 10.1002/cncr.27745

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase 2 study of two doses of bortezom

A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma

✍ S. Jagannath; B. Barlogie; J. Berenson; D. Siegel; D. Irwin; P. G. Richardson; R 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 190 KB

Tanespimycin and bortezomib combination

Tanespimycin and bortezomib combination treatment in patients with relapsed or relapsed and refractory multiple myeloma: results of a phase 1/2 study

✍ Paul G. Richardson; Asher A. Chanan-Khan; Sagar Lonial; Amrita Y. Krishnan; Mich 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 382 KB

A phase I safety study of enzastaurin pl

A phase I safety study of enzastaurin plus bortezomib in the treatment of relapsed or refractory multiple myeloma

✍ Irene M. Ghobrial; Nikhil C. Munshi; Brianna N. Harris; Peipei Shi; Nichole M. P 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 209 KB 👁 2 views

A573 Phase I Trial of CCI-779 and Weekly

A573 Phase I Trial of CCI-779 and Weekly Bortezomib in Relapsed and/or Refractory Multiple Myeloma

✍ Roccaro, AM; Leduc, R; Nelson, M; Sam, A; Chuma, S; Colson, K; O'Connor, K; Ghob 📂 Article 📅 2009 🏛 CIG Media Group, LP. 🌐 English ⚖ 92 KB

Weekly bortezomib in combination with te

Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1/2, open-label, dose-escalation study

✍ Irene M Ghobrial; Edie Weller; Ravi Vij; Nikhil C Munshi; Ranjit Banwait; Meghan 📂 Article 📅 2011 🏛 The Lancet 🌐 English ⚖ 210 KB

Updated survival analyses after prolonge

Updated survival analyses after prolonged follow-up of the phase 2, multicenter CREST study of bortezomib in relapsed or refractory multiple myeloma

✍ Sundar Jagannath; Bart Barlogie; James R. Berenson; David S. Siegel; David Irwin 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 85 KB